Scopio Labs expands Siemens alliance to drive digital hematology

Business Handshake Intelligence Social

Scopio Labs and Siemens Healthineers have expanded their alliance to include the global distribution of Scopio's Full-Field Bone Marrow Aspirate (FF-BMA) application in aiding the diagnosis of blood disorders.

To support the needs of pathology and hematopathology laboratories, FF-BMA eliminates the need for manual microscopy in bone marrow aspirate analysis and enables viewing bone marrow smears and results remotely through a secure hospital network, according to Scopio. For hematologists, hematopathologists, and lab scientists, the product is designed for full-field digital imaging at 100x magnification and artificial intelligence (AI)-powered decision support. 

Scopio Labs CEO and co-founder Itai Hayut said the technology is a significant step toward clinical laboratory digitization, efficiency, and standardization.

The company added that its alliance with Siemens Healthineers already includes the global distribution of Scopio's X100 and X100HT imaging platforms with the Full-Field Peripheral Blood Smear (FF-PBS) application. 

The FF-BMA application received de novo clearance from the U.S. Food and Drug Administration (FDA), Scopio announced in April 2024. Dr. Adam Bagg, professor of pathology and laboratory medicine the University of Pennsylvania's Perelman School of Medicine, led the BMA study that was submitted to the FDA. 

"Scopio's FF-BMA Application addresses the urgent need for digital innovation amid the rising prevalence of hematologic conditions and healthcare demands," Bagg said at the time. "By optimizing digital workflows and enabling unique remote review of entire smears, we are hopeful this technology can help enhance efficiency across the board."

Page 1 of 180
Next Page